CYTEA BIO – Modular Cell Therapy for Complex Pathologies

MODULAR NEXT GENERATION

CELL THERAPY

NEW & INNOVATIVE THERAPIES

CYTEA|BIO is developing therapeutic products by combining genetically unmodified effector cells and novel targeting ligands.

OUR PATENTED PIN™ PLATFORM ENABLES PRACTICALLY LIMITLESS COMBINATIONS OF EFFECTOR MECHANISMS AND TARGETING LIGANDS, BUILDING NEW AND INNOVATIVE THERAPIES WITHOUT NEED FOR DRUG DISCOVERY, WITH UNRIVALLED EFFICACY, SAFETY AND ECONOMICS.

4+

(POTENTIAL PRODUCT CANDIDATES)

(THE COMPANY)

OUR COMPANY

CYTEA|BIO IS A PRE-CLINICAL STAGE BIOTECHNOLOGY COMPANY BASED IN MONTPELLIER DEDICATED TO THE DEVELOPMENT OF INNOVATIVE CELL IMMUNOTHERAPY PRODUCTS

6+

(YEARS OF ACADEMIC RESEARCH BEHIND THE PLATFORM)

CYTEA|BIO HAS DEVELOPED AND PATENTED A VERSATILE AND MODULAR CELL THERAPY PLATFORM (PIN™ PLATFORM). THE PLATFORM IS UNIQUE IN ITS APPROACH TO UTILIZE UNMODIFIED (THEREFORE POTENT AND SAFE) IMMUNE EFFECTOR CELLS TARGETED TO PATHOLOGICAL CELLS THROUGH RECOGNITION LIGANDS OCCUPYING NATURAL RECEPTORS ON THE THERAPEUTIC CELL SURFACE. THE PIN™ PLATFORM ENABLES VIRTUALLY ANY HUMANIZED MONOCLONAL ANTIBODY TO BE EMPLOYED AS A TARGETING LIGAND AS WELL AS A WIDE RANGE OF FC – BASED CONSTRUCTS.

SIMPLE Fc ENGINEERING ENABLES LIGANDS TO BE FIRMLY BOUND TO THE THERAPEUTIC CELL DURING MANUFACTURE.
THE PIN™ PLATFORM SUPPORTS THERAPEUTIC USES OF BOTH ALLOGENEIC AND AUTOLOGOUS EFFECTOR CELLS WITHOUT ANY MODIFICATIONS. WHEN COMBINED WITH APPROPRIATE SINGLE OR MULTIPLE LIGANDS, AN ALMOST UNLIMITED NUMBER OF DRUG SUBSTANCES ARE POSSIBLE, PROVIDING SENSING, TARGETING ACTIVATION AND POTENT THERAPEUTIC EFFECT WITH LOW DEVELOPMENT RISK AND POSITIVE ECONOMICS.

MORE ABOUT OUR COMPANY

(CONCEPT)

OUR TECHNOLOGY

PLATFORM

EFFECTOR CELLS AND TARGETING LIGANDS

Unmodified human effector cells armed with engineered antibodies or engineered Fc ligands, selected to target disease markers

MORE ABOUT OUR PLATFORM

PIPELINE

TREATING VARIOUS PATHOLOGIES

ROBUST PRE-CLINICAL POC ACHIEVED WITH ANTI-CD20 ARMED ALLOGENEIC NATURAL KILLER (NK) CELLS. LEAD TUMOR DEVELOPMENT PROGRAM FOR PRIMARY AND RECURRENT GLIOBLASTOMA MULTIFORME (GBM).